| | Introduction
Rheumatoid arthritis is a debilitating and life-long disease that is estimated to affect approximately 5 million people in the seven major markets. The launch of anti-TNF products over six years ago and more recent novel target biologic therapies have added significantly to the treatment options, but have resulted in a crowded market for moderate to severe patients.
Scope
Disease overview including epidemiology, physician estimated diagnosis rates and severity split, including mild to severe and early active disease
Breakdown of treatment trends in the following markets: US, Japan, France, Germany, Italy, Spain and the UK
PCPs and rheumatologists surveyed to capture the treatment of the ranging severities with traditional NSAIDs, COX-2s, traditional and biologic DMARDs
Comparative brand assessment on the key attributes of Enbrel, Remicade, Humira, Orencia, Rituxan/MabThera, Kineret and methotrexate
Report Highlights
Inclusion of relevant early active RA patients in clinical studies will assist timely approval in this indication, increasing the patient base for any RA product. Definition of ‘early’ RA requires a balance between the physician ideal of less than 12 months, giving the best patient response, and capturing a substantial proportion of the market.
Physicians estimate nine months from disease onset to diagnosis. 25% of RA patients are estimated to be severe, and take an average of four months before the first DMARD is prescribed, being methotrexate in 60% of physicians. It can be 18-23 months before a severe patient is likely to use a biologic.
Anti-TNF therapy is expected to continue to dominate the first-line biologic use. Humira is perceived to be the most effective in terms of disease modification, indicating a very positive future status for this brand, but Remicade and Kineret could lose the brand battle if perception on certain attributes doesn't improve.
Reasons to Purchase
Use estimated treatment class patient numbers to forecast product use across the seven major markets
Exploit physician perceptions of key brands on clinical and market attributes, to differentiate products in the crowded rheumatoid arthritis market
Understand differential treatment in niche populations such as severe and early active rheumatoid arthritis
More Info
|
| | | Introduction
There are no FDA-approved second-line chemotherapy options for hormone refractory prostate cancer, indicating a great unmet need, with a large potential market for an agent such as Spectrum's satraplatin, which could offer key advantages due to its oral administration profile.
Scope
Analysis of the regulatory and commercial potential for SPPI's oral satraplatin, the first agent to demonstrate activity in second-line HRPC patients
Interviews with 5 prostate cancer specialists regarding trends in the treatment of this disease and the potential role for a second-line HRPC option
Highlights
Given its novel oral administration profile and promising efficacy data from a small European trial, if approved, we believe Spectrum Pharmaceuticals' (SPPI) and GPC Biotech's (GPCB) satraplatin could become a widely popular treatment option for second-line hormone-refractory prostate cancer (HRPC) patients.
Pending results from the recently enrolled Phase III SPARC trial, we anticipate that satraplatin, a third generation platinum agent, could be approved for HRPC as early as mid-2007 and forecast significant revenues for the companies.
Reasons to Purchase
Predict the regulatory and commercial potential for SPPI's oral satraplatin through in-depth analysis based on interviews with leading experts
Anticipate likely changes in the future market dynamics for hormone-refractory prostate cancer therapies upon possible launch of oral satraplatin More Info
|
| | | Introduction
Digital imaging products and CEREC form the basis for growth for Sirona Dental Systems, while accounting for nearly two-thirds of revenues, and will therefore be essential to the newly formed combination of Schick Technologies and Sirona.
Scope
Analyzes the market outlook for Sirona's digital imaging and CEREC technologies, two high end dental technologies
Datamonitor interviewed seven dentists, including four opinion leaders, in the course of research
Highlights
The 'new' Sirona Dental Systems will be heavily dependent on its CEREC esthetics system and its digital radiography products to drive annual growth. However, we expect significant challenges to continued revenue growth.
We expect the ongoing conversion from traditional x-rays to digital imaging to be rapid and extensive, but competition is on the rise.
Despite a strong reputation, the high cost of CEREC is a significant impediment to low-volume practices, or those practices that are not 'cutting edge'.
Reasons to Purchase
Predict the commercial potential for Sirona Dental Systems and its key technologies through in-depth analysis based on interviews with leading experts
Anticipate likely changes in the future market dynamics for dental imaging technologies caused by the merger of Sirona and Schick Technologies
More Info
|
| | | Introduction
Palatin Technologies' bremelanotide (PT-141) is a novel melanocortin receptor agonist that is believed to be the only agent currently in development for the treatment of both erectile dysfunction (ED) and female sexual dysfunction (FSD).
Scope
Explores the regulatory and commercial potential for PTN's bremelanotide, a novel agent in development for male and female sexual dysfunction
Interviews with 7 urologists familiar with bremelanotide and its clinical data and potential for the treatment of male and female sexual dysfunction
Highlights
While there would appear to be much potential for an agent that can improve libido in both male and female patients without acting directly on the vascular system, we believe that unclear efficacy of PTN's bremelanotide and substantial regulatory risk diminish the potential this agent in the treatment of male and female sexual dysfunction.
Pending results from the two Phase IIb trials which are expected later this year, we forecast US bremelanotide revenues well below the blockbuster potential estimated by some Wall Street analysts.
Reasons to Purchase
Understand the commercial potential for Palatin Technologies' Bremelanotide through in-depth analysis based on interviews with leading experts
Anticipate likely changes in the future market dynamics for erectile dysfunction therapies if approval of bremelanotide occurs More Info
|
| | | The global diagnostics market is undergoing radical change; novel technologies driven by miniaturization and advances in genomics will enhance the role of diagnostics in the healthcare market, allowing more tests to be performed at the point-of-care and facilitating the shift towards personalized medicine. “Innovation in Diagnostics” examines the advances in the rapidly growing field of molecular technologies that are enabling personalized healthcare to move into mainstream medicine. New opportunities in infectious disease testing, molecular oncology and pharmacogenomics are explored in detail, enabling you to understand the forces that are driving in vitro diagnostics (IVDs) into centre stage of the healthcare arena. Understand the changing relationship between IVD companies and the pharmaceutical industry, assess the convergence of IVDs and medical imaging, and develop an understanding of new technologies that will influence diagnostic product development and drug development programs. More Info
|
| | | Introduction
Stimulated by sales of atypical antipsychotics for bipolar depression, and despite the launch of generic risperidone, the global bipolar disorder market will grow until 2011, when revenues will peak at $6.6 billion. The market will begin to decline thereafter owing to the launch of generic versions of the leading atypical antipsychotics, quetiapine, olanzapine, and ziprasidone from 2011 onwards.
Scope
Analysis of patient potential, unmet needs and clinical trial design in bipolar disorder
Overview of drugs in pre-registration, Phase III, II and I; with analysis of key companies involved in the market
Detailed profiles of key compounds in development for use in bipolar disorder, with forecasts of drug revenues to 2015
Discussion of indication expansion strategies and insight from key industry opinion leaders
Highlights
AstraZeneca will be the first company to bring an atypical antipsychotic to the bipolar depression market as a monotherapy, following demonstration of efficacy with quetiapine. Pfizer will maintain a strong schizophrenia franchise by releasing asenapine to buffer the loss in revenue due to genericization of ziprasidone.
Solvay/Wyeth/Lundbeck's bifeprunox will be the leading market entrant in terms of bipolar disorder specific sales revenue. These companies appear to be seeking initial license for bifeprunox in the bipolar depression indication, a tactic that will both increase the commercial viability of the drug and save time/money.
Despite the commercial success of Lamictal (lamotrigine) and Depakote (valproate), the late-stage bipolar disorder pipeline only includes one anticonvulsant class molecule, Novartis' licarbazepine.
Reasons to Purchase
Understand unmet needs in the bipolar disorder market based on key opinion leader comments
Benchmark key late-stage bipolar disorder compounds against current market leaders
Assess the global (US, Japan, five major EU) sales forecasts of late-stage pipeline drugs; and examine their clinical and commercial potential
More Info
|
| | | Introduction
In 2007, more than 3 million new cases of solid tumors are forecast to be diagnosed across the seven major pharmaceutical markets, obviously representing an enormous market potential. Lower incidence tumor types are becoming increasingly attractive to drug developers, due to high levels of unmet need which can result in significant financial rewards.
Scope
Examination of the solid cancer pipeline with in-depth clinical and commercial profiles of Phase III candidates for 17 tumor types Seven major pharmaceutical sales forecasts for Phase III pipeline products through to 2016 with product-specific assumptions Segmentation and analysis of the current solid tumor pipeline by developmental phase, drug class and indication Insight and analysis of market potential including commercial opportunity, epidemiology, commonalities across cancers and discussion of unmet needs
Highlights
The current solid tumor pipeline contains at least 707 unique agents, 9% of which are in late-phase development. These products cover a vast array of anticancer drug classes, including antihormonal therapies, cytotoxics, gene therapies, immunotherapies, photodynamic therapies, radiotherapeutics, targeted therapies and therapeutic vaccines. The late-phase pipeline contains equal amounts of cytotoxics and targeted therapies. The Phase I and II pipelines contain more than twice as many targeted therapies as cytotoxics. As such, it is clear that increasing diversity in terms of drug targets may result in greater treatment options in years to come if positive clinical data is generated. Despite high levels of unmet need and relatively healthy pipelines for most indications, no major breakthroughs are expected by current late-phase products aside from incremental increases in efficacy and reduced toxicity. This indicates a heavy reliance on the earlier-phase pipeline for further breakthroughs in terms of treatment of solid tumors.
Reasons to Purchase
Identify key drugs and companies within the oncology pipeline based on sales forecasts to 2016 and Datamonitor drug assessment Characterize unmet need and poorly served markets within oncology and assess the potential for pipeline products to provide satisfaction Assess the shifting oncology market dynamic and how future treatment of solid tumors will incorporate pipeline products
More Info
|
| | | Introduction
The PD market is set to continue to grow over the next 7 years, reaching over $2.37 billion in 2013, a 39% increase from 2006 levels. Combinations, reformulations, and indication expansions will drive the majority of this growth, with key brands expected to be Novartis/Orion's Stalevo, GlaxoSmithKline's (GSK's) Requip Modutab, and UCB-Schwarz's Neupro.
Scope
Analysis of patient potential, unmet needs and clinical trial design in PD Overview of key marketed brands, late- and early-stage pipeline drugs, and cell/gene therapies. Indication- and country-specific sales volume and value forecasts to 2016 of marketed brands, generics, and key late-stage pipeline drugs. Identification of future market events that are expected to affect PD drug revenues.
Highlights
GSK's Requip Modutab will become the market leading PD brand in 2011. It will be intuitive for prescribers to believe that sustained activation of dopamine receptors with Requip Modutab could have a significant clinical benefit over pulsed agonism with standard drugs. New pipeline drugs will need to be innovative to compete in an increasingly crowded market. While this is evident in Eisai's E2007, it is lacking in Merck-Serono/Newron's safinamide. Early studies with cell/gene therapies show great promise for significantly slowing the progression of the disease. However, these alternative approaches will not significantly impact the sales of pharmaceuticals over the forecast period 20072016.
Reasons to Purchase
Benchmark key late-stage PD compounds against current market leading brands. Assess country-specific (US, Japan, France, Germany, Italy, Spain and the UK) sales forecasts of key late-stage pipeline drugs and marketed brands. Understand unmet needs and opportunities in the PD market based on key opinion leader comments.
More Info
|
| | | Introduction
The current epilepsy market boasts a wide range of treatment options and has recently reached a state of maturity. The market value across the 7MM grew by just 2.3% from 2005 to $3.2 billion in 2006. However, imminent change to the market in the near to mid term will be brought about by the occurrence of key patent expiries and new drugs launches.
Scope
This report focuses on drugs used to treat epilepsy, with indication- and country-specific sales value and volume forecasts to 2016. Assessment of current and future opportunities and threats in the epilepsy market across the 7MMs and in individual regions. Identification of future market events expected to impact epilepsy-specific anticonvulsant drug revenues over the next decade. Case study analysis of successful lifecycle management strategies and provision of key recommendations to ensure revenue growth.
Highlights
Despite advances in epilepsy treatment over the past 15 years, the efficacy of current anticonvulsants remains limited, with approximately 2030% of patients continuing to suffer from refractory seizures. As such, in an increasingly crowded market, targeting refractory epilepsy patients continues to present a potentially lucrative opportunity. Focusing on epilepsy rather than diversifying into other secondary CNS indications has played a pivotal role for UCB in ensuring Keppra's market leadership and ongoing strong uptake. Demonstrating a solid commitment to the disease will be viewed favorably by neurologists and will promote brand loyalty. This, in turn will provide long-term growth. Keppra's pediatric epilepsy indication expansions over the past 2 years have served to expand its patient base. In view of the high prevalence of childhood epilepsy and high level of unmet need in this patient group, gaining approval in the pediatric population remains an attractive means of increasing revenue and strengthening brand loyalty.
Reasons to Purchase
Quantify the future size of the epilepsy market, in terms of prescription volume and value, in each of the seven major markets. Assess the impact of future events such as patent expiries, indication expansions, and new product launches on the sales of key marketed brands. Identify key lifecycle management strategies and market opportunities that can ensure growth in the increasingly competitive epilepsy market.
More Info
|
| | | Introduction
With the seven triptan brands continuing to dominate acute migraine treatment and Ortho-McNeil's Topamax (topiramate) driving sales in the prophylactic market, 7MM revenues of anti-migraine drugs increased by 8.1% from 2005 to $3.7 billion in 2006. The US accounted for 80% of the 7MM total in 2006, Whilst in the 5EU, France is the largest market for migraine-specific drug sales.
Scope
This report focuses on acute and prophylactic drugs used to treat migraine, with indication- and country-specific sales and volume forecasts to 2016 Assessment of current and future opportunities and threats in the migraine market across the 7MMs and in individual regions Analysis and quantification of future market events expected to impact anti-migraine drug revenues over the next decade Case study analysis of successful lifecycle management strategies and scenario forecasts provide further market insight and key recommendations
Highlights
GSK has executed a number of well-timed lifecycle management strategies that have ensured Imitrex's market leadership. However, Imitrex's impending patent expiry will result in generic sumatriptan flooding the US market in late 2008, and crucial delays to Trexima's launch will signal the end of GSK's dominance of the migraine market. There remains substantial opportunity in the migraine prophylaxis market. In spite of US Topamax patent expiry in 2008, the large number of untreated patients and poor tolerability profiles of existing treatments means the prophylactic market will remain highly attractive over the forecast period. Menstrual migraine (MM) represents an unknown, yet potentially rewarding market opportunity. Endo and Vernalis's Frova (frovatriptan) awaits the FDA's decision on its application for the short-term prevention of MM. This outcome will be crucial to the drug's future and will also influence other triptan manufacturers' decision to pursue MM.
Reasons to Purchase
Quantify the future size of the migraine market, in terms of prescription volume and value, in each of the seven major markets Assess the impact of future events such as patent expiries, indication expansions, and new product launches on the sales of key marketed brands Identify key lifecycle management strategies and market opportunities that can ensure growth in the competitive anti-migraine pharmaceutical arena
More Info
|
|
|
|